Psychedelic Bulletin 229 tracks SAMHSA's expert meeting, Beckley's route to Eli Lilly, Turnbull's push on BOL-148, and Compass' broader treatment ambitions

US psychedelic policy and industry developments converge around federal agency attention, biotech strategy, and expanding clinical ambitions. SAMHSA brings experts together as public-health institutions weigh how psychedelics may fit future mental health responses, while companies and nonprofits position themselves for influence in that shift. Beckley's path toward Eli Lilly signals how large pharmaceutical players may enter the field through partnerships, assets, or research pipelines rather than only in-house discovery. Turnbull's continued emphasis on BOL-148 highlights interest in non-hallucinogenic or modified psychedelic-adjacent compounds that may promise different risk-benefit profiles. Compass' discussion of indication expansion points to a business model built on taking psychedelic-assisted treatment beyond an initial target condition if trials and regulators allow. Possible involvement from the US Department of Veterans Affairs underscores how veterans' mental health care could become a major arena for adoption, reimbursement, and real-world implementation.